MedTrace Logo

Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects

NCT03742492 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-05-30

No results posted yet for this study

Summary

Evidence has suggested that omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have an important role in promoting cardiovascular health. However, the currently available scientific literature describing the postprandial effects and bioavailability of these fatty acids, particularly when they are incorporated into high protein food item, like canned tuna, is far from conclusive.

The aim of this study is to evaluate the acute bioavailability of EPA + DHA enriched canned tuna and its acute effects on cardiovascular risk markers, in healthy human volunteers.

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Meal containing canned tuna + fish oil (5 g EPA + DHA)

Meal containing canned tuna + fish oil (5 g EPA + DHA)

DIETARY_SUPPLEMENT

Meal containing canned tuna + soybean oil

Meal containing canned tuna + soybean oil

Sponsors & Collaborators

  • Center for Health Technology and Services Research

    collaborator OTHER

  • NOVA Medical School

    collaborator OTHER

  • Universidade do Porto

    lead OTHER

Principal Investigators

  • Conceição Calhau, PhD · CINTESIS, NOVA Medical School

  • Luís Azevedo, PhD · CINTESIS, Faculty of Medicine of the University of Porto

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-19
Primary Completion
2019-06-30
Completion
2019-07-31

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742492 on ClinicalTrials.gov